Sector: HealthcareIndustry: Drug Manufacturers - GeneralCIK: 0000882095
Market Cap169.62 Bn
P/E19.91
P/S5.76
Div. Yield0.02
ROIC (Qtr)0.19
Total Debt (Qtr)24.94 Bn
Revenue Growth (1y) (Qtr)4.70
Add ratio to table...
About
Gilead Sciences, Inc., often recognized by its stock symbol GILD, is a prominent player in the biotechnology and pharmaceutical industry. This company has made significant strides in the development and commercialization of innovative medicines over the past three decades. Its operations span various life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer.
Gilead's primary business activities revolve around the discovery, development, and commercialization of these groundbreaking medicines. The company's reach extends to...
Gilead Sciences, Inc., often recognized by its stock symbol GILD, is a prominent player in the biotechnology and pharmaceutical industry. This company has made significant strides in the development and commercialization of innovative medicines over the past three decades. Its operations span various life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer.
Gilead's primary business activities revolve around the discovery, development, and commercialization of these groundbreaking medicines. The company's reach extends to numerous countries and regions, demonstrating its global impact.
Revenue for Gilead primarily comes from the sale of its approved products, such as Biktarvy, Genvoya, Descovy, Odefsey, Complera/Eviplera, Truvada, Stribild, Sunlenca, Veklury, Epclusa, Vemlidy, Harvoni, Yescarta, Tecartus, and Trodelvy. These products cater to diverse markets, including HIV, viral hepatitis, COVID-19, and cancer. For instance, Biktarvy, Genvoya, and Descovy are used to treat HIV infection in both adults and pediatric patients. Epclusa and Harvoni, on the other hand, are used to treat chronic hepatitis C virus infection. Veklury, the company's COVID-19 product, is used to treat the disease in certain adults and pediatric patients. Yescarta, Tecartus, and Trodelvy are used to treat various types of cancer, including lymphoma and breast cancer.
In the highly competitive landscape of the pharmaceutical and biotechnology industry, Gilead maintains a strong position. Its competitive advantages include a robust portfolio of approved products, an extensive pipeline of investigational products, and a wide network of collaborations and partnerships.
Gilead's customers include hospitals, clinics, healthcare providers, patients, and payers. The company's products are marketed and distributed through its own commercial teams and/or in conjunction with third-party distributors and corporate partners.
Among the many brands and trade names associated with Gilead's products are Biktarvy, Genvoya, Descovy, Odefsey, Complera/Eviplera, Truvada, Stribild, Sunlenca, Veklury, Epclusa, Vemlidy, Harvoni, Yescarta, Tecartus, and Trodelvy. Each of these names represents a significant contribution to the medical field, providing vital treatments for various diseases.
The company’s HIV portfolio continues to expand, with treatment and prevention sales growing consistently year over year. In 2025, Biktarvy and Descovy drove a 6% increase in HIV revenues, and the newly launched twice yearly injection, YES2GO, is already exceeding its early coverage goals. The launch data show 90% payer coverage and a 90% zero co‑pay rate, indicating rapid market penetration that should sustain a strong sales trajectory into 2026. Furthermore, the company projects an 8% rise in HIV revenue for 2026, which would lift the overall base business growth into the high single digit range.
A diversified product pipeline is adding significant commercial upside across therapeutic areas. Gilead is targeting four additional launches in 2026, including Trodelvy for first line metastatic triple negative breast cancer and the investigational once daily bictegravir–lenacapavir regimen, Viclen. Each of these candidates has already earned positive phase three data or is poised for regulatory submission, positioning the company to generate multiple new revenue streams within the next two years. The company’s commitment to disciplined R&D spend—maintaining R&D expense at a low single digit growth rate—ensures that new launches can be supported without eroding margins.
The liver disease platform is also experiencing robust uptake, with Libdelzi achieving a 42% sequential sales increase and securing over 50% of second line primary biliary cholangitis market share. The recent approval of Libdelzi in 2024 and its subsequent real world adoption have created a high‑margin product that is now an integral part of the company’s core portfolio. As the company plans to further expand Libdelzi indications with the IDEAL study, additional revenue lift is anticipated in the 2027–2028 window. This demonstrates a clear upside to the company’s “diversification strategy” that has been a key theme over the past six years.
The oncology program has shown remarkable momentum, with Trodelvy sales rising 6% year over year and gaining first line indication support from the ASCENT phase three data. Trodelvy’s NCCN guideline endorsement for both PD‑L1 positive and negative metastatic triple negative breast cancer should drive broader adoption, potentially doubling the current patient base. The company’s oncology pipeline is complemented by phase three updates on other indications—such as endometrial cancer and non‑small cell lung cancer—creating a breadth of opportunity across multiple high‑volume markets. These developments reinforce the belief that the oncology side is moving beyond a single product dependency into a multi‑product revenue engine.
Financially, the company reported a 5% increase in fourth quarter sales, with a product gross margin consistently above 86%. Non‑GAAP operating income is projected to exceed $13.8 billion in 2026, supporting a strong return to shareholders, evidenced by a 63% free cash flow payout rate in 2025. The company’s cash position of $10.6 billion at year‑end provides ample liquidity to fund future launches and potential acquisitions without compromising growth initiatives. This solid balance sheet, combined with disciplined expense management, should insulate the company from market volatility.
The company’s HIV portfolio continues to expand, with treatment and prevention sales growing consistently year over year. In 2025, Biktarvy and Descovy drove a 6% increase in HIV revenues, and the newly launched twice yearly injection, YES2GO, is already exceeding its early coverage goals. The launch data show 90% payer coverage and a 90% zero co‑pay rate, indicating rapid market penetration that should sustain a strong sales trajectory into 2026. Furthermore, the company projects an 8% rise in HIV revenue for 2026, which would lift the overall base business growth into the high single digit range.
A diversified product pipeline is adding significant commercial upside across therapeutic areas. Gilead is targeting four additional launches in 2026, including Trodelvy for first line metastatic triple negative breast cancer and the investigational once daily bictegravir–lenacapavir regimen, Viclen. Each of these candidates has already earned positive phase three data or is poised for regulatory submission, positioning the company to generate multiple new revenue streams within the next two years. The company’s commitment to disciplined R&D spend—maintaining R&D expense at a low single digit growth rate—ensures that new launches can be supported without eroding margins.
The liver disease platform is also experiencing robust uptake, with Libdelzi achieving a 42% sequential sales increase and securing over 50% of second line primary biliary cholangitis market share. The recent approval of Libdelzi in 2024 and its subsequent real world adoption have created a high‑margin product that is now an integral part of the company’s core portfolio. As the company plans to further expand Libdelzi indications with the IDEAL study, additional revenue lift is anticipated in the 2027–2028 window. This demonstrates a clear upside to the company’s “diversification strategy” that has been a key theme over the past six years.
The oncology program has shown remarkable momentum, with Trodelvy sales rising 6% year over year and gaining first line indication support from the ASCENT phase three data. Trodelvy’s NCCN guideline endorsement for both PD‑L1 positive and negative metastatic triple negative breast cancer should drive broader adoption, potentially doubling the current patient base. The company’s oncology pipeline is complemented by phase three updates on other indications—such as endometrial cancer and non‑small cell lung cancer—creating a breadth of opportunity across multiple high‑volume markets. These developments reinforce the belief that the oncology side is moving beyond a single product dependency into a multi‑product revenue engine.
Financially, the company reported a 5% increase in fourth quarter sales, with a product gross margin consistently above 86%. Non‑GAAP operating income is projected to exceed $13.8 billion in 2026, supporting a strong return to shareholders, evidenced by a 63% free cash flow payout rate in 2025. The company’s cash position of $10.6 billion at year‑end provides ample liquidity to fund future launches and potential acquisitions without compromising growth initiatives. This solid balance sheet, combined with disciplined expense management, should insulate the company from market volatility.
The company’s recent guidance for 2026 sales sits at the low end of analyst expectations, with a projected $29.6 billion to $30 billion versus an industry consensus of $30.2 billion. This shortfall reflects the company’s own acknowledgment of a 2% headwind from pricing agreements and Affordable Care Act uncertainties, signaling that market forces could exert more pressure than initially anticipated. The guidance revision came after a market reaction that saw shares decline nearly 2% following the earnings announcement, indicating investor concerns about growth prospects. Such a downward adjustment signals a cautious outlook that could weigh on the stock’s valuation relative to peers.
The reliance on the twice yearly injection, YES2GO, presents significant execution risk that management has not fully addressed. Although coverage is at 90% and the company claims strong early adoption, the drug’s success hinges on sustained patient compliance with a semi‑annual schedule, which may be challenging given the need for clinic‑based administration. The company admitted that it is still gathering data on persistence and refill rates, which remain uncertain and could undermine the projected $800 million sales target. The potential for high upfront marketing and specialty pharmacy support costs also threatens to compress margins if patient uptake stalls.
The oncology launch, particularly Trodelvy for first line metastatic triple negative breast cancer, remains contingent on regulatory approvals that have not yet materialized. While phase three data are positive, the drug is still awaiting FDA decision on the new indication, and any delay or conditional approval could postpone revenue realization and increase regulatory costs. Additionally, the oncology market is highly competitive, with multiple ADCs and immunotherapies vying for the same patient cohort, potentially eroding market share and pricing power. These factors introduce a risk that the oncology segment may not deliver the projected incremental revenue in the near term.
The cell therapy division has already experienced a 7% decline in sales in 2025, and the company projects a 10% revenue decline in 2026 due to intensified competition from both existing and emerging CAR‑T platforms. The division’s dependence on a few high‑price products such as Yescarta and Tecartus exposes it to reimbursement pressures and potential substitution by alternative therapies that may offer similar efficacy at lower cost. The company’s own statements highlight “competitive headwinds” and the need for new entrant vigilance, suggesting that its current market position is precarious. Such dynamics could constrain the growth potential of a historically significant revenue generator for the firm.
The company’s pricing environment is tightening, with a recent agreement to lower Medicaid pricing for select products, which could impact the net price across the HIV portfolio. Management acknowledged the possibility of “lower price channels” and “proposed changes to the Affordable Care Act,” indicating that future pricing reductions may be more aggressive than the company has anticipated. If net pricing compresses further, the company’s margin erosion could outpace its growth in sales volumes, particularly in the high‑volume HIV prevention market. This scenario would materially affect the company’s profitability outlook.
The company’s recent guidance for 2026 sales sits at the low end of analyst expectations, with a projected $29.6 billion to $30 billion versus an industry consensus of $30.2 billion. This shortfall reflects the company’s own acknowledgment of a 2% headwind from pricing agreements and Affordable Care Act uncertainties, signaling that market forces could exert more pressure than initially anticipated. The guidance revision came after a market reaction that saw shares decline nearly 2% following the earnings announcement, indicating investor concerns about growth prospects. Such a downward adjustment signals a cautious outlook that could weigh on the stock’s valuation relative to peers.
The reliance on the twice yearly injection, YES2GO, presents significant execution risk that management has not fully addressed. Although coverage is at 90% and the company claims strong early adoption, the drug’s success hinges on sustained patient compliance with a semi‑annual schedule, which may be challenging given the need for clinic‑based administration. The company admitted that it is still gathering data on persistence and refill rates, which remain uncertain and could undermine the projected $800 million sales target. The potential for high upfront marketing and specialty pharmacy support costs also threatens to compress margins if patient uptake stalls.
The oncology launch, particularly Trodelvy for first line metastatic triple negative breast cancer, remains contingent on regulatory approvals that have not yet materialized. While phase three data are positive, the drug is still awaiting FDA decision on the new indication, and any delay or conditional approval could postpone revenue realization and increase regulatory costs. Additionally, the oncology market is highly competitive, with multiple ADCs and immunotherapies vying for the same patient cohort, potentially eroding market share and pricing power. These factors introduce a risk that the oncology segment may not deliver the projected incremental revenue in the near term.
The cell therapy division has already experienced a 7% decline in sales in 2025, and the company projects a 10% revenue decline in 2026 due to intensified competition from both existing and emerging CAR‑T platforms. The division’s dependence on a few high‑price products such as Yescarta and Tecartus exposes it to reimbursement pressures and potential substitution by alternative therapies that may offer similar efficacy at lower cost. The company’s own statements highlight “competitive headwinds” and the need for new entrant vigilance, suggesting that its current market position is precarious. Such dynamics could constrain the growth potential of a historically significant revenue generator for the firm.
The company’s pricing environment is tightening, with a recent agreement to lower Medicaid pricing for select products, which could impact the net price across the HIV portfolio. Management acknowledged the possibility of “lower price channels” and “proposed changes to the Affordable Care Act,” indicating that future pricing reductions may be more aggressive than the company has anticipated. If net pricing compresses further, the company’s margin erosion could outpace its growth in sales volumes, particularly in the high‑volume HIV prevention market. This scenario would materially affect the company’s profitability outlook.